The relatively poor yield of genetic screening to date in nonfamilial cases is exemplified by the French C3 glomerulopathy cohort, in which mutations in one of three genes (Cfh, Cfi, and MCP) was reported in only 18% of all patients screened.21 This evidence concerns the gene CD46 and complement 3 glomerulopathy.